FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1291PDF: 217HTML: 86Supplementary: 60 -
Anticoagulation in obese patients: challenges and strategies
1827PDF: 261HTML: 195XML: 77 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
4PDF: 1 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
1PDF: 0 -
PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS A. Naassan, R. Fatima, M. Naassan, C. Chisholm | Lakeridge Health, R.S. McLaughlin Durham Regional Cancer Centre, Department of Oncology, Oshawa, ON, Canada
5PDF: 0 -
PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella1,2, V. Coluccio3, M. Luppi1, M. Marietta1 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; 3Department of Hematology, Unità Sanitaria Locale di Modena, Italy
434PDF: 0 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
6PDF: 1 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
1PDF: 0 -
OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY A. Ramírez1, A. Orozco2, A. Sánchez3, F. Villalpa1, S. Burgos2, G. Cesarman3, G. Rodríguez1, D. Vieyra2, J. Álvarez4, G.M. Flores3, S. González1, D. Martínez2, B. Cabello3, R. Espinoza3, O. Fernández3 | 1Myeloma-clinic Hematology service, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México City, México; 2Myeloma-clinic Hematology service, Instituto Nacional de Nutrición Salvador Zubirán, México City, México; 3Myeloma-clinic Hematology service, Instituto Nacional de Cancerologçia, México City, Mexico; 4Centro Médico Nacional 20 de Noviembre, México City, Mexico
3PDF: 0 -
CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
520PDF: 0 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
1PDF: 0 -
PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy
586PDF: 0 -
PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva1, V. Bitsadze1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Khisamieva1, J. Gris1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
2PDF: 0 -
PO22 | Early detection and management of PICC-related thrombosis in oncohematologic patients through serial ultrasound monitoring: a prospective observational study S. Laurenti, M. Schneeberger, G. Rosati, A. Pozzi, M. Padrini, R. Vacchelli, A. Morotti | University of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy
461PDF: 0 -
PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY G. Gerotziafas1|3|4|5, S. Allakhverdieva6, P. Henrique Fernandes Do Carmo Las Casa1, P. Van Dreden1|2, J. Fareed3, N. Lomakin6 , I. Zotova6, L. Buryachkovskaya7 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; 2Clinical Research, Diagnostica Stago, Gennevilliers, France; 3Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 4Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 5VAS-European Independent Foundation in Angiology/Vascular Medicine Milan, Italy; 6Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 7Federal State Budgetary Institution «National Medical Research Centre of Cardiology Named After Academician E. I. Chazov» of the Ministry of Health of the Russian Federation, Moscow, Russia
1PDF: 0 -
PO14 | SYMPTOM BURDEN IN PATIENTS WITH CANCER AND THROMBOEMBOLISM: A POPULATION-BASED MATCHED COHORT STUDY D. Siegal1|2, Z. O’Neill1|2, L. Nguyen3, N. Liu3, M. Carrier1|2, R. Sutradhar3|4 | 1Ottawa Hospital Research Institute, Ottawa; 2Department of Medicine, University of Ottawa, Ottawa; 3ICES, Toronto, Canada; 4Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
1PDF: 0 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
1PDF: 0 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
3PDF: 0 -
PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti1|2|3, P. Gomez-Rosas1|4|5, S. Bolognini1, C. Ticozzi1, D. Romeo1, F. Schieppati1|3, L. Barcella1|3, F. Petrelli6, A. D'Alessio7, R. Labianca7, A. Falanga1|2|3 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 3ERN EuroBloodNet; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; 5Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 6Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; 7Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators
0PDF: 0
1 - 24 of 24 items
